ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting

    Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment

    Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan

    Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
  • Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting

    Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis

    Mihaela Maruseac1, Patrick Durez2,3, Adrien Nzeusseu Toukap4 and Maria Stoenoiu5, 1Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 4Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 5Rheumatology, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium

    Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…
  • Abstract Number: 55 • 2018 ACR/ARHP Annual Meeting

    Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice

    Tadashi Okano1, Kentaro Inui2, Hideki Ueyama3, Kumi Orita3, Tatsuya Koike4 and Hiroaki Nakamura2, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Osaka City University Graduate School of Medicine, Osaka, Japan, 4Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Adipose derived stem cell (ADSC) is one of the stem cells produced by adipose tissue which can be collected easily and in large quantities.…
  • Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting

    Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

    Jeffrey R. Curtis1, Jürgen Wollenhaupt2, Katerina Chatzidionysiou3, Sander W. Tas4, Lisy Wang5, Harry Shi6, María Montoro7, Petra Neregård8, Palle Dahl9 and Vassilis Tsekouras10, 1University of Alabama at Birmingham, Birmingham, AL, 2Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Madrid, Spain, 8Pfizer Inc, Stochholm, Sweden, 9Pfizer Inc, Ballerup, Denmark, 10Pfizer Inc, Athens, Greece

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…
  • Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting

    Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model

    Ruby J. Siegel1, Solomon A. Agere1, Anil K. Singh1 and Salahuddin Ahmed2,3, 1Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, 2Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 3Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
  • Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting

    Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib

    Burkhard Moeller1, Axel Finckh2, Jose Maria Alvaro-Gracia3, Godehard Scholz1, Daniel Aletaha4, Francesca Biondo5, Sander Strengholt6, Jose L Rivas7, Carol A Connell8 and Harry Shi9, 1Inselspital-University Hospital, Bern, Switzerland, 2University Hospital of Geneva, Geneva, Switzerland, 3Hospital Universitario de La Princesa, Madrid, Spain, 4Medical University of Vienna, Vienna, Austria, 5Pfizer Inc, Rome, Italy, 6Pfizer Inc, Capelle aan den IJssel, Netherlands, 7Pfizer SLU, Madrid, Spain, 8Pfizer Inc, Groton, CT, 9Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
  • Abstract Number: 64 • 2018 ACR/ARHP Annual Meeting

    Dietary Magnesium Modulates the Intestinal Microbiome and T Cell Subsets

    Teresina Laragione1, Carolyn Harris1 and Percio S. Gulko2, 1Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Several studies have demonstrated that Magnesium (Mg) has a key role in the immune responses. Our previous studies showed that a short-term low Mg…
  • Abstract Number: 1981 • 2018 ACR/ARHP Annual Meeting

    A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity

    Wenhui Wang1, Amit Lahiri2, Teresina Laragione2, Jun Zhu1 and Percio S. Gulko2,3, 1Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune joint disease. RA is pathologically heterogeneous with multiple contributing factors. While there has been a…
  • Abstract Number: 70 • 2018 ACR/ARHP Annual Meeting

    Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients

    Geoffrey M. Thiele1, Michael J. Duryee2, Jacob D. McGowan1, Logan M. Duryee1, Lynell W. Klassen3, James R. O'Dell3, Bryant R. England4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:   Malondialdehyde-acetaldehyde adducts (MAA) are products of oxidative stress that modify self-proteins and stimulate potent cellular and humoral immune responses. We have previously demonstrated…
  • Abstract Number: 1982 • 2018 ACR/ARHP Annual Meeting

    An Integrative Rheumatoid Arthritis Network for Elucidating Molecular Mechanisms Underlying RA Severity

    Wenhui Wang1, Teresina Laragione2, Amit Lahiri2, Jun Zhu1 and Percio S. Gulko3, 1Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a pathologically heterogeneous disease with multiple contributing factors. Many models have been developed to study RA severity and progression, and…
  • Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting

    Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis

    Veena K. Ranganath1, David Elashoff2, Jenny Brook3, Ami Ben-Artzi4, Geraldine Navarro5, Lynnette Avedikian-Tatosyan6, George Karpouzas7, William Martin5, Tanaz A. Kermani5, Soo Choi5 and Gurjit S. Kaeley8, 1Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, 2David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, 3Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 4Medicine, Cedars, Beverly Hills, CA, 5Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 6Healthcare Partners, Los Angeles, CA, 7Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 8Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL

    Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
  • Abstract Number: 1412 • 2017 ACR/ARHP Annual Meeting

    Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Hyun Jung Yoo1,2, Jeong Yeon Kim1, Shin Eui Kang1, Ji Seok Yoo3, Yong Nam Lee3, Dong Goo Lee3, Ji Soo Park1, Eun Bong Lee4, Eun Young Lee4 and Yeong Wook Song2,5, 1Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South), 3Central R&D Institute, Yungjin Pharm Co., Ltd., Suwon, Korea, Suwon, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplastic synovial pannus tissue, which mediates destruction of cartilage and bone. Fibroblast-like synoviocyte (FLS) are a key component…
  • Abstract Number: 1940 • 2017 ACR/ARHP Annual Meeting

    Immunologic Synovitis Score: A New Score for Synovial Membrane Characterization in Inflammatory and Non-Inflammatory Arthritis

    Aurélie Najm1,2, Benoît Le Goff MD PhD2,3, Frédéric Blanchard1, Jérome Amiaud4, Céline Charrier5 and Veit Krenn6, 1INSERM U1238 University of medicine, PHY-OS Laboratory, Nantes, France, 2Rheumatology, Nantes University Hospital, Nantes, France, 3UNR1238 University of medicine, PHY-OS Laboratory, Nantes, France, 4UMR1238 University of medicine, PHY-OS Laboratory, Nantes, France, 5UNMR1238 University of medicine, PHY-OS Laboratory, Nantes, France, 6Zytologie und Molekulare Diagnostik, MVZ-Zentrum für Histologie, Trier, Germany

    Background/Purpose: General Synovitis score (GSS) has been developed by Krenn et al in order to discriminate inflammatory arthritis (IA) and non-inflammatory arthritis (NIA) (1). This…
  • Abstract Number: 2436 • 2017 ACR/ARHP Annual Meeting

    MiR-146a Upregulates the TLR4/NF-κb Signaling Pathway to Promote Cytokine Expression and Synovial Fibroblast Proliferation in Rheumatoid Arthritis

    Yuan-hao Wu1,2, Wei Liu1, Lei Zhang3, Bin Xue3, Yi Wang3, Xiao-ya Liu3, Yang Ji4, Ran Duan3, Yue Cai3 and Bo Zhang3, 1Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 2Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China, 3First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 4The 272nd Hospital of Chinese People's Liberation Army, Tianjin, China

    Background/Purpose: To investigate the role of miR-146a in the activation of toll-like receptor-4 (TLR4)/ nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, and…
  • Abstract Number: 2704 • 2017 ACR/ARHP Annual Meeting

    Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis

    Ryan Galea1,2, Hendrik Nel1,2, Meghna Talekar1,2, Suzanne Cole3, Karyn Cochlin4, Shannon Hitchcock5, Bijun Zeng1,2, Suman Yekollu1,2, Jamie Rossjohn6, Hugh Reid7, Ravi Malaviya5, Dave Shealy8, Brendan O'Sullivan1,2 and Ranjeny Thomas1,2, 1Dendright Pty Ltd, Brisbane, Australia, 2University of Queensland Diamantina Institute, Brisbane, Australia, 3Immunology, Janssen Research and Development, Spring House, PA, 4Immunology, Janssen Research and Development, Springhouse, PA, 5Janssen Research and Development, Springhouse, PA, 6Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, 7Monash University, Melbourne, Australia, 8Janssen Research and Development, Spring House, PA

    Background/Purpose: Current treatments to control autoimmune arthritis and vasculitis use broadly immunosuppressive drugs, associated with undesirable side effects. Antigen-specific immunological tolerance strategies are preferable to…
  • « Previous Page
  • 1
  • …
  • 170
  • 171
  • 172
  • 173
  • 174
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology